Compare · INCR vs NVO
INCR vs NVO
Side-by-side comparison of Intercure Ltd. (INCR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 4099.6x INCR ($47.8M).
- Over the past year, INCR is down 45.7% and NVO is down 42.9% - NVO leads by 2.8 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for INCR).
- NVO has more recent analyst coverage (25 ratings vs 1 for INCR).
- Company
- Intercure Ltd.
- Novo Nordisk A/S
- Price
- $0.87+0.45%
- $43.95+0.16%
- Market cap
- $47.8M
- $195.92B
- 1M return
- -5.00%
- -4.04%
- 1Y return
- -45.71%
- -42.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 4
- Recent ratings
- 1
- 25
Intercure Ltd.
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INCR
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
- SEC Form 20-F filed by Intercure Ltd.
- SEC Form 3 filed by new insider Rabinovich Alexander
- SEC Form 3 filed by new insider Michelson Lennie Grinbaum
- SEC Form 3 filed by new insider Granot Alon Shmuel
- SEC Form 3 filed by new insider Salton David
- SEC Form 3 filed by new insider Cohen Amos
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S